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Abstract
Background: We have previousy reported on a Phase II study of S-1 monotherapy as a first line, combination therapy of S-1 plus 
cisplatin as a second line, and weekly paclitaxel monotherapy as a third line therapy in patients with advanced gastric carcinomas. The 
median survival time (MST) of patients over the whole course of treatment was not previously calculated because 12 out of 19 patients 
had not yet succumbed. Since then, we have calculated the MST for this study and herein report our findings.
Patients and Methods: Between 2002 and 2005, 19 patients were enrolled in this study. Chemotherapy consisted of either 60 mg/m2 of 
S-1 for 4 weeks at 6-week intervals, a combination of 60 mg/m2 S-1 for 3 weeks and 60 mg/m2 cisplatin on day 8 at 5-week intervals, or 
60 mg/m2 paclitaxel at days 1, 8, and 15, at 4-week intervals. The regimens were repeated until the occurrence of unacceptable toxicities, 
disease progression, or patient noncompliance. The primary end point was the overall survival.
Results: The median survival time was 774 days. The response rates were 33.3% (3/9), 12.5% (1/8), and 0% (0/4) after the first, second, 
and third line chemotherapies, respectively. The major adverse hematological toxicity was leukopenia, which reached grades 3–4 in 
all lines of chemotherapy investigated. In addition, the major adverse non-hematological toxicity was anorexia, which reached grade 
3–4 in second line chemotherapy, and no deaths were attributable to the adverse effects of the drugs.
Conclusion: This sequential therapy was an effective treatment for advanced gastric cancer with acceptable toxic side-effects. We 
considered this therapy to be effective because of the smooth transition to the next regimen.
Keywords: advanced gastric cancer, recurrent gastric cancer, S-1, cisplatin, paclitaxel, phase II study, first line chemotherapy, second 
line chemotherapy, third line chemotherapyrino et al
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Introduction
S-1  is  a  novel  oral  fluorouracil  antitumor  drug  that 
contains a combination of 3 pharmacological agents: 
tegafur (FT), a 5-Fluorouracil (5-FU) prodrug; 5-chloro-
2,4-dihydroxypyridine  (CDHP),  which  inhibits  the 
activity of dihydropyrimidine dehydrogenase (DPD); 
and potassium oxonate (Oxo), which reduces the gas-
trointestinal toxicity of 5-FU.1 A phase II study of S-1 
showed a 44%–53.6% response rate to the drug and a 
median survival time (MST) of 207–298 days.2,3 This 
drug has gradually been accepted as the front-line che-
motherapy in Japan for the treatment of unresectable, 
resected but uncured, and recurrent gastric cancers.
In 2008, Koizumi et al described the results from 
the SPIRITS trial4 and noted that the median overall 
survival was significantly longer in patients assigned to 
S-1 plus cisplatin than in those treated with S-1 alone. 
Since this report, many institutions in Japan have cho-
sen to use S-1 plus cisplatin as the first line chemo-
therapy for advanced and recurrent gastric cancer.
In our previous report,5 we evaluated S-1, S-1 plus 
cisplatin, and paclitaxel as chemotherapeutic regimens 
for treatment of advanced gastric cancer by measuring 
the objective response rate (RR), overall survival, and 
the safety profile, for the use of these therapies as first, 
second, and third line chemotherapeutic regimens. In 
this previous report, MST was not calculated because 
more than half of the patients were alive. In this study, 
we evaluated MST for the 19 patients.
patients and Methods
Patient eligibility
A total of 19 patients were enrolled in this study 
between June 2002 and December 2005. To be eligible 
for inclusion, the patients had to have histologically or 
cytologically confirmed gastric adenocarcinoma that 
was either unresectable (n = 3), palliatively resected 
(n = 10), or recurrent (n = 6) (Table1). The patients 
had received no prior chemotherapy and were able to 
take S-1 orally. Patients with recurrent gastric cancers 
were included if 3 or more months had elapsed after 
the last post-operative adjuvant chemotherapy. After 
informed consents were received from patients, one 
group of patients received S-1, which was admin-
istered daily for two 4-week periods, separated by 
a  2-week  interval  for  the  first  line  chemotherapy. 
A  dose  reduction  was  not  allowed;  however,  the 
treatment schedule was changed in some cases to 5 
consecutive days of treatment followed by 2 days 
of  rest  per  week.  This  treatment  schedule  was 
repeated for 4 weeks, followed by 2 weeks of rest. 
The regimen was changed upon patient presentation 
of grade 3 toxicity, progressed disease, or elevated 
tumor markers. However, if grade 3–4 toxicity was 
observed  after  the  first  line  chemotherapy,  then  a 
second line chemotherapy was administered after the 
patient recovered from the toxicity. If the second-line 
chemotherapy was refused by the patient who origi-
nally received S-1, then weekly Paclitaxel was given 
as the second line chemotherapy. The patients were 
also required to meet the following criteria: age of 
75 years or less, amenable to oral administration of 
drugs, a Karnofsky performance score of 60, a life 
expectancy of at least 3 months, and an adequate 
hematological status (defined as having a total leu-
kocyte  count  greater than 3,500  per mm3, neutro-
phil count of greater than 1,500 per mm3, platelet 
count greater than 100,000 per mm3, serum creati-
nine  levels  under  1.5  mg/dl,  total  serum  bilirubin 
Table . Characteristics of enrolled patients.
characteristcs  number of 
patients
(%) 
Total number of patients 19
Age (years) 
  Mean ± sD (range)
 
61.3 ± 1.4 (38–75)
sex 
  Male 
  Female
 
12 
7
 
63.2 
36.8
Karnofsky performance 
status  
  80–100
 
 
19
 
 
100
histological type  
(Japanese classification) 
  Differntiated 
  Undifferentiated
 
 
6 
13
 
 
31.6 
68.4
Primary treatment 
    Curative gastrectomy  
(recurrent cases) 
Palliative gastrectomy 
Without gastrectomy
 
6 
 
10 
3
 
31.6 
 
52.6 
15.8
Target lesions 
    Primary 
Peritoneal dissemination 
Lymph node metastasis 
Liver metastasis
 
3 
14 
5 
2
 
15.8 
73.3 
26.3 
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under 1.5 mg/dl, aspartate aminotransferase (AST), 
and alanine aminotransferase (ALT) levels less than 
2 times the upper limit of the normal range). Patients 
were excluded from the study if they had any other 
current  or  prior  malignancies,  active  uncontrolled 
infections  or  other  diseases,  or  a  neurological  or 
mental  disease  that  prevented  adequate  compre-
hension  of  information.  The  pretreatment  evalu-
ation consisted of a complete history and physical 
examination, blood count, serum biochemistry, and 
computed tomography (CT) of the chest and abdo-
men. All patients gave informed consent before the 
initiation of treatment.
study design (Fig. 1)
First line chemotherapy
S-1 was administered orally twice daily after breakfast 
or dinner, at 80 mg/m2/day for 4 weeks, followed by 
2 weeks of rest. During the course of the treatment, 
the patients were evaluated for complete blood counts 
(CBC), biochemical and physical examinations every 
2  weeks,  and  for  the  presence  of  tumor  markers 
(CEA, CA19-9, STn and SLX) on every 4 weeks. The 
treatment response was then evaluated by CT every 
2 months.
second line chemotherapy
S-1 was administered at the same dosage as the first line 
chemotherapy. S-1 was administered for 3 weeks followed 
by 2 weeks of rest. On day 8, S-1 was combined with 
cisplatin at 60 mg/m2. The patients were pretreated with 
8 mg dexamethasone and 10 mg azasetron hydrochrolide 
diluted in 50 ml of saline given intravenously 30 minutes 
prior to treatment. Chemotherapy was then administered 
by intravenous infusion, consisting of 60 mg/m2 cispla-
tin administered over 120 minutes. During the course 
1st line: S-1   80 mg/m2
S-1
Day 1 28 42
Day 1 21 8 35
Day 1 15 8 28
2nd line: S-1  80 mg/m2, cisplatin  60 mg/m2
Cisplatin
S-1
3rd line: Paclitaxel 60 mg/m2
Figure . Protocols of First, second, and Third line chemotherapy regimens.
First line chemotherapy: s-1 was administered orally twice daily after breakfast or dinner, at 80 mg/m2/day for 4 weeks, followed by 2 weeks of rest.
second line chemotherapy: S-1 was administered at the same dosage as the first line chemotherapy. S-1 was administered for 3 weeks followed by 
2 weeks of rest. On day 8, s-1 was combined with cisplatin at 60 mg/m2.
Third line chemotherapy: Paclitaxel was administered at 60 mg/m2 on days 1, 8, and 15 of a 4-week treatment cycle.rino et al
  Clinical Medicine Insights: Oncology 2010:4
of the treatment, the patients were evaluated for CBC 
values,  biochemical  and  physical  examinations  every 
2–3 weeks, and for expression of tumor markers (CEA, 
CA19-9, STn and SLX) every 4 weeks. The treatment 
response was evaluated every 2 months by CT.
Third line chemotherapy
Paclitaxel was administered at 60 mg/m2 on days 1, 8, 
and 15 of a 4-week treatment cycle. Prior to paclitaxel 
administration, patients were given 50 mg oral diphen-
hydramine  and  20  mg  intravenous  dexamethasone 
with 50 ml saline over 30 min, 50 mg intravenous 
ranitidine  hydrochloride  with  50  ml  saline  over 
30 min, and 10 mg intravenous azasetron hydroch-
rolide with 50 ml saline over 30 min. Paclitaxel was 
administered by intravenous infusion and consisted 
of 60 mg/m2 over 60 minutes.
All patients were admitted to the hospital for the 
first intravenous treatment of the second and third line 
chemotherapies. Subsequent intravenous treatments 
were performed on an outpatient basis. If hemato-
logical or non-hematological toxicities of grade 3 or 
higher occurred, or if the patient so requested, the 
treatment was halted.
study evaluations
All responses were assessed by physical examina-
tion, direct visualization, examination of the upper 
  gastrointestinal tract after barium ingestion, gastrofi-
broscopy, and CT. Tumor evaluation was performed 
every two months according to the Response Evalu-
ation  Criteria  In  Solid Tumors  (RECIST),  and  the 
responses  were  confirmed  by  radiography  within 
2 weeks. All adverse events were graded using the 
National Cancer Institute Common Toxicity Criteria 
(NCI-CTC, versions 2.0 and 3.0) at each treatment 
cycle.  In  the  event  of  toxicity,  chemotherapy  was 
postponed until the symptoms had resolved.
survival analysis
The length of survival was measured from the time of 
treatment initiation up until patient death. The Kaplan-
Meier method was used to calculate the survival rate. 
The difference between the curves was assessed using 
the log-rank test. Differences with probability (p) val-
ues less than 0.05 were considered to be statistically 
significant.  Statistical  calculations  were  conducted 
using the Dr. SPSS II for Windows software program.
Results
Patient characteristics
The demographic features of the 19 patients enrolled 
in this study are shown in Table 1. All patients were 
assessed for response and toxicity. The median patient 
age was 61.3 years (range: 38–75 years); 12 patients 
were male (63.2%) and 7 were female (36.8%), with 
all patients being in good general health (Karnofsky 
performance status: 80–100). All patients had histo-
logically confirmed adenocarcinomas, with a total of 
6 differentiated and 13 undifferentiated adenocarcino-
mas. The most frequently observed sites of tumors were 
peritoneal dissemination in 14 patients, lymph nodes 
metastases in 5 patients, followed by the primary tumor 
site in 3 patients and liver metastases in 2 patients.
The first line therapy was performed in 19 cases, 
and on average 6.2 courses of administration could 
be performed (range: 0–20, median: 5). The treatment 
schedule was changed to 5 consecutive days in three 
cases  (range:  9–15,  median:  10).  The  second  line 
therapy was performed in 13 cases, with 2.8 courses 
performed  on  average  (range:  1–7,  median:  2). 
Third line therapy was performed in 13 cases with 
6.2  courses  on  average  (range:  0–24,  median:  4). 
Cases with 0 courses in the first line and third line 
  treatments  were  the  result  of  patient  noncompli-
ance due to side effects, as well as rapidly increasing 
lesions. The fourth line and subsequent treatments 
were  performed  in  10  cases.  None  of  the  patients 
underwent any subsequent surgery.
For the tumor markers, we used CEA and CA19-9. 
Even if PD was not observed in CT, etc., the regi-
men was changed from first line to second line che-
motherapy in cases in which the CEA level increased 
from 2.7 to 4.6 or from 19.2 to 24.9, or in which the 
CA19-9 level increased from 48 to 113.
Efficacy
There  were  measurable  lesions  in  9  patients  who 
underwent  first  line  therapy,  8  patients  in  second 
line therapy, and 4 patients who underwent third line 
therapy. In first line therapy, one case of CR (Fig. 2) 
and  2  cases  of  PR  were  identified;  in  second  line 
therapy, there was one case of PR, but in third line 
therapy neither PR nor CR were found. The RR were 
33.3%, 12.5%, and 0% for each therapy. In CR for 
first line therapy, there were episodes of lymph node Phase II study of s-1, s-1 plus cisplatin, and weekly paclitaxel therapy
Clinical Medicine Insights: Oncology 2010:4  
  metastasis, while in PR there were liver metastases, 
peritoneal dissemination, and primary tumors. There 
was liver metastasis in PR after second line therapy.
survival
The mean follow-up time was 952.6 days with a range 
of 44 to 2295 days. The MST was 774 days (Fig. 3). In 
patients with non-curative resection (n = 10), the MST 
was 853 days. In patients without resection (n = 3), the 
MST was 522 days. In patients with recurrent cancers 
(n = 6), the MST was 376 days. There were no signifi-
cant differences between the non-curative resection, 
non-resection, and recurrent patients (Fig. 4).
Toxicity
Leucopenia  followed  by  anemia  was  the  most 
  frequent hematological toxicity, and was a side-effect 
of at least grade 3 severity. In first line therapy, 1 
case of leucopenia and 1 case of neutropenia (10.5%) 
were  observed;  in  second  line  therapy,  3  cases  of 
  leucopenia and 2 cases of anemia (23.1%); and in 
third line therapy, 2 cases of leucopenia and 1 case of 
anemia (23.1%) were observed. Loss of appetite was 
the most frequently observed non-hematological tox-
icity. In first line therapy, 1 case of stomatitis, 1 case of 
lachrymation, and 1 case of limb numbness (10.5%); 
in second line treatments, 1 case of nausea, 4 cases 
with a loss of appetite, 2 cases of diarrhea, 1 case of 
fatigue, and 1 case of abdominal pain (46.2%); and in 
third line therapy, not a single case was found to have 
severe toxicities (Table 2).
Discussion
S-1 has been the most widely used anti-cancer drug 
for advanced or recurrent gastric cancer in Japan for 
several years. S-1 inhibits tumors and disseminated 
peritoneal metastases in gastric carcinoma patients 
as confirmed by Mori et al6 in a mouse model of 
gastric  cancer. A  high  concentration  of  5-FU  was 
detected in intraperitoneal tumor lesions of the S-1 
  treatment group, and prolonged survival rates were 
also observed. However, the mechanism by which 
– paraaortic lymph node meatatasis
– hydronephrosis
Figure . Lymph node metastasis and hydronephrosis. Left figure shows paraaortic lymph node metastasis and hydronephrosis. S-1 treatment alone 
was started for the patient. After 2 months, there was no lymph node swelling or hydronephrosis, as shown in the right figure.rino et al
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5-FU concentrations are maintained in the peritoneal 
cavity is not yet known.
In more than 4,000 patients administered S-1 for 
gastric  cancer,  25%  have  experienced  grade  3  or 
higher toxicities, and their MST was 8.3 months.7 We 
herein observed an occurrence of grade 3 or higher 
toxicities  in  9.4%  of  patients,  a  response  rate  of 
38.4%, and a median survival rate of 343 days in the 
patients who received S-1 monotherapy for advanced 
or recurrent gastric cancer.8
In a report comparing S-1 plus cisplatin adminis-
tration to S-1 administration alone, the frequency of 
patients with side-effects of grade 3 or higher severity 
were 43.5% and 22.5%, respectively, for each admin-
istration, and in combined therapy, side-effects were 
approximately twice as frequent as in single therapy, 
with 36.8% and 25.9% of RR, respectively, which is 
markedly higher with combined therapy. However, 
MST was 319 days and 322 days, respectively, which 
indicates that the therapies did not contribute in any 
way to the extension of survival time.9
In  2008,  Koizumi  et  al  reported  the  SPIRITS 
trial4 that median overall survival was significantly 
longer  in  patients  treated  with  S-1  plus  cisplatin 
(13.0 months, IQR 7.6–21.9) than in those assigned 
to  S-1  alone  (11.0  months,  5.6–19.8;  hazard  ratio 
for  death,  0.77;  95%  CI  0.61–0.98;  P  =  0.04). 
Progression-free survival was significantly longer in 
patients assigned to S-1 plus cisplatin than in those 
assigned  to  S-1  alone  (median  progression  free 
survival  6.0  months  [3.3–12.9]  versus  4.0  months 
[2.1–6.8];  P    0.0001).  They  reported  a  higher 
  frequency  of  grade  3  or  4  adverse  events  includ-
ing  leucopenia,  neutropenia,  anemia,  nausea,  and 
MST 774 days 
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Figure . Over all survival curve (n = 9). The median survival time was 774 days.Phase II study of s-1, s-1 plus cisplatin, and weekly paclitaxel therapy
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anorexia in the group assigned to S-1 plus cisplatin 
than in the group assigned to S-1 alone. For example, 
grade 3 or 4 neutropenia accounted for 11% and 40%, 
respectively, in S-1 and S-1 plus cisplatin, and grade 
3 or 4 anorexia was 6% and 30%, respectively.
Since this report, many institutions in Japan have 
implemented S-1 plus cisplatin as first line chemo-
therapy  for  advanced  and  recurrent  gastric  cancer. 
However, we chose to use S-1 alone as first line che-
motherapy. With the additional results from the SPIR-
ITS trial, therapeutic regimens may be more carefully 
selected for the treatment of gastric cancer. In this study, 
patients with this report, side-effects with at least grade 
3 toxicities consisted of non-hematological toxicities 
in 10.5% and 46.2% and hematological toxicities in 
10.5% and 23.1%, of S-1 and S-1 plus cisplatin treat-
ment groups, respectively. S-1 plus cisplatin treatment 
administration following S-1 treatment did not signifi-
cantly increase the number of side-effects.
The median treatment regimen for each patient was 
five cycles (range 0–20), in our study or three cycles 
(range 1–12) of S-1 treatment alone in the SPIRITS 
trial.  The  median  for  each  patient  was  two  cycles 
(range 1–7), four cycles (range 1–11) of S-1 plus cis-
platin treatment, respectively. The cycles of S-1 plus 
cisplatin treatment in our study were fewer in number 
than those used in the SPIRITS trial. The RR in our 
study was lower than in the SPIRITS trial. Although 
a comparison cannot be made because non-curative 
resection patients were not included in the subjects of 
the SPIRITS trial, the MST in our study was longer 
than in the SPIRITS trial.4 At our institute, we imple-
ment the S-1 plus cisplatin regimen on an outpatient 
basis.10 However, at many institutes in Japan, the S-1 
plus cisplatin regimen is implemented on an inpatient 
basis. Furthermore, because side effects occur more 
frequently in the S-1 plus cisplatin regimen than in a 
regimen using S-1 alone, there are cases in which the 
non-curative resection patients (n = 10)
MST = 853 days
recurrent patients (n = 6)
MST = 376 days
non-resection patients (n = 3)
MST = 589 days
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Figure . survival curves for all primary treatments. In the non-curative resection patients (n = 10), the median survival time (MsT) was 853 days. In 
the non-resection patients (n = 3), the MsT was 522 days. In the recurrent patients (n = 6), the MST was 376 days. There were no significant differences 
among the non-curative resection, non- resection and recurrent patients.rino et al
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Table . Adverse events, according to regimen group.
Regimen Type Grade        
        %  and 
s-1 (n = 19)
diarrhea 2 3 0 0 0
constipation 1 0 0 0 0
nausea 2 1 0 0 0
anorexia 1 5 0 0 0
vomiting 1 1 1 0 5.3
headache 2 0 0 0 0
fatigue 7 2 0 0 0
stomatitis 0 5 1 0 5.3
dizziness 1 1 0 0 0
AsT,ALT 2 1 0 0 0
lachrymation 3 1 0 0 0
photophobia 3 0 1 0 5.3
dysgeusia 1 1 0 0 0
alopecia 1 0 0 0 0
pigmentation 3 1 0 0 0
nail changes 1 1 0 0 0
conjunctivitis 1 0 0 0 0
numbness of limbs 2 0 1 0 5.3
abdominal pain 1 0 0 0 0
edema 1 1 0 0 0
allergic rhinitis 1 1 0 0 0
anemia 0 1 0 0 0
leukopenia 0 1 1 0 5.3
neutropenia 0 0 1 0 5.3
s-1 + CDDP (n = 13)
diarrhea 2 0 2 0 15.4
nausea 0 0 1 0 7.7
anorexia 2 1 4 0 30.8
fatigue 2 2 1 0 0
AsT,ALT 0 1 0 0 0
pigmentation 2 0 0 0 0
alopecia 1 0 0 0 0
abdominal pain 0 1 1 0 7.7
edema 0 1 0 0 0
hypotension 1 0 0 0 0
epistaxis 1 0 0 0 0
rash 1 0 0 0 0
anemia 0 1 2 0 15.4
leukopenia 0 1 3 1 30.8
neutropenia 0 0 2 0 15.4
lymphopenia 0 0 0 1 7.7
Weekly paclitaxel (n = 13)
diarrhea 2 1 0 0 0
constipation 0 1 0 0 0
nausea 3 0 0 0 0
anorexia 1 0 0 0 0
fatigue 3 0 0 0 0
dizziness 0 1 0 0 0
AsT, ALT 1 1 0 0 0
lachrymation 1 0 0 0 0
dysgeusia 1 0 0 0 0
numbness of limbs 2 1 0 0 0
(Continued)Phase II study of s-1, s-1 plus cisplatin, and weekly paclitaxel therapy
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S-1 plus cisplatin regimen cannot be selected as the 
first line chemotherapy. We therefore believe that our 
regimen would be useful in such cases.
We adopted this approach because the paclitaxel 
used in this regimen showed no cross-resistance and 
had a completely different side-effect profile.11 At the 
beginning of this therapy, weekly paclitaxel therapy 
for gastric cancer had not been established, and we 
determined a dose based on the reports for other types 
of cancer and tumors. In ovary cancers, 80 mg/m2 of 
paclitaxel is the maximum tolerable dose, but it has 
been  reported  that  the  incidence  of  neuropathy  is 
frequently  found  with  60  mg/m2  of  paclitaxel.12  In 
breast and lung cancers, 60 mg/m2 of paclitaxel was 
effective.13,14 From these reports, we decided to per-
form weekly paclitaxel therapy with 60 mg/m2 as the 
subsequent chemotherapy following S-1 plus cispla-
tin. In recent reports of weekly paclitaxel therapy for 
gastric cancers, the dose of paclitaxel is 80 mg/m2, and 
we also provided weekly paclitaxel therapy as the sec-
ond line chemotherapy, following S-1 in pretreatment, 
with a dose of 80 mg/m2. In this therapy, the RR was 
0%, MST was 495 days, and 11.8% hematological tox-
icity with at least grade 3 in severity was recognized.15 
In this therapy, the dose of paclitaxel was 60 mg/m2, 
and after treatment with S-1 and S-1 plus cisplatin, 
neither CR nor PR developed. However, non-hema-
tological toxicity was not found, and hematological 
toxicity was reported in only 23.1% of patients. The 
average number of cycles performed was 6.2, with a 
median value of 4. As the third line therapy, following 
S-1 and S-1 plus cisplatin (protocols with a relatively 
high frequency of side-effects), a dose of 80 mg/m2 
may be achievable, but this will require further study.
Therefore, in this study the response rate was low, but 
survival time was excellent. The MST was approximately 
2.1 years (774 days). We believe that this was caused by 
the smooth transition between regimens. It is difficult to 
switch from one type of chemotherapy to another regi-
men if there is no obvious PD, but even in cases of perito-
neal dissemination in which PD is difficult to determine, 
we switched regimens upon increased tumor markers 
and palpation of the Douglas cavity. Therefore, we were 
able to switch to the next regimen without any hesitation, 
because the next regimen had already been determined.
In conclusion, this report is of the results from the 
first  line  chemotherapy  with  S-1  alone,  second  line 
therapy with S-1 plus cisplatin, and third line therapy 
with weekly paclitaxel. In this therapy, direct curative 
effects for tumors were not universally successful, but 
improved survival rates were observed, and the side-
effects  were  minor.  Considering  the  possibility  for 
adverse events and toxicities, S-1 plus cisplatin should 
not be the first line chemotherapy administered to gas-
tric cancer patients.
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